Skip to main content
Equibles
PURE logo

PURE · Pure Bioscience, Inc. · Metrics

Track PURE — free

Use PURE with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PURE.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.09 +0.01 (+12.64%) At close · Oct 23
Rebalance outlook locked
Going-concern doubt — flagged Jun 15, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Our history of recurring operating losses, and negative cash flows from operating activities give rise to substantial doubt regarding our ability to continue as a going concern.”
View the 10-Q filed Jun 15, 2026
Market Cap
$11.70M
Shares
130.02M
Volume · Oct 23 22.5K Avg daily vol (3M) 31.87K

PURE metrics

69 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.09
Market cap
$11.70M

Price action

20 metrics
Price change (1W)
+19.7%
Price change (30D)
+41.5%
Price change (3M)
+12.5%
Price change (6M)
+28.6%
Price change (YTD)
+125.0%
Price change (1Y)
+12.5%
Trailing year
Price change (5Y)
-74.3%
52-week high
$0.10
52-week low
$0.04
Change from 52-week high
-10.0%
Change from 52-week low
+125.0%
Annualized volatility
154.6%
Annualized volatility (3M)
204.6%
Beta
0.5
RSI (14D)
59.8
Price vs SMA 50
+24.2%
Price vs SMA 200
+34.7%
Avg volume (3M)
31,869
Relative volume
0.7
Average dollar volume
$2,262

Company

3 metrics
Sector
Consumer Defensive
Industry
Household & Personal Products
Shares outstanding
130.02M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
7.1×
reciprocal yield 14.1%
EV / EBITDA
—
EV / EBIT
—
P / sales
4.8×
reciprocal yield 20.7%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-18.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
58.9%
Operating margin
-79.2%
Trailing 12 months
Net margin
-91.2%
Gross profit (TTM)
$1.43M
Operating profit (TTM)
−$1.92M
Net income (TTM)
−$2.21M
Trailing 12 months
Diluted EPS (TTM)
$-0.01
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.02
Gross profit per diluted share (TTM)
$0.01
Operating profit per diluted share (TTM)
$-0.02
EBITDA per diluted share (TTM)
$-0.03
Net income per diluted share (TTM)
$-0.02
Operating cash flow per diluted share (TTM)
$-0.02
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$0.00
Stock compensation per diluted share (TTM)
$0.00
Book value per share
$-0.05

Growth

11 metrics
Revenue growth YoY
+3.5%
Year over year
Net income growth YoY
—
Revenue (TTM)
$2.42M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
-0.9%
Year over year · fewer shares
Revenue CAGR (3Y)
+6.6%
Revenue CAGR (5Y)
-20.5%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-141.5%
Debt / equity
—
Current ratio
0.4
EBITDA (TTM)
−$1.98M
Free cash flow (TTM)
—
Quick ratio
0.4
Interest coverage
-4.9
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$5.51M
Latest balance sheet
Cash & equivalents
$983,000
Total assets
$1.56M
Total debt
$6.50M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$1.78M
Capital expenditures (TTM)
—
R&D (TTM)
$312,000
SG&A (TTM)
$3.03M
Stock compensation (TTM)
$177,000
R&D / revenue
12.9%
Stock compensation / revenue
7.3%

Ownership (13F)

9 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
0.0%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
32 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1006028 CUSIP 74621T209 Visit website Investor relations